Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US [0.03%]
纠正：在美国，抗CD38单克隆抗体联合硼替佐米、来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤患者的成本
Niodita Gupta-Werner,Vipin Khare,Brian Macomson et al.
Niodita Gupta-Werner et al.
[This corrects the article DOI: 10.36469/001c.141714.]. Keywords: cost analysis; daratumumab; isatuximab; mu...
Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective [0.03%]
从美国医疗保健角度来看成人特发性膜性肾病所致肾病综合征患者的蛋白尿治疗：Acthar凝胶与标准疗法的成本效益分析
Jas Bindra,Ishveen Chopra,Kyle Hayes et al.
Jas Bindra et al.
Background: Proteinuria, a critical marker of glomerulosclerosis, poses a challenge in idiopathic membranous nephropathy (iMN), particularly when standard treatments fail. Acthar® Gel, a US Food and Drug Administration-approved treatment o...
Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer [0.03%]
雄激素受体途径抑制剂治疗后前列腺特异性抗原降低：转移性非去势敏感型前列腺癌患者疾病进展的现实世界比较研究
Shawn Du,Carmine Rossi,Ibrahim Khilfeh et al.
Shawn Du et al.
Background: Prostate-specific antigen (PSA) has been used as both a screening tool and a marker for treatment response for advanced prostate cancer. With the introduction of androgen receptor pathway inhibitor (ARPI)-based treatment for met...
Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US [0.03%]
美国一线治疗不适合移植的新诊断多发性骨髓瘤患者的抗CD38单克隆抗体与硼替佐米、来那度胺和地塞米松联合使用的费用
Niodita Gupta-Werner,Vipin Khare,Brian Macomson et al.
Niodita Gupta-Werner et al.
Background: The efficacy of the combination of bortezomib, lenalidomide, and dexamethasone with daratumumab (DVRd) or isatuximab (IsaVRd) for the frontline treatment of transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) has...
Optimizing Oncology Generic Medication Selection in the Gulf Region: Expert Consensus and MCDA Tool Development [0.03%]
肿瘤学通用药物的选择优化：海湾地区的专家共识和MCDA工具开发
Anas Hamad,Omar AbdulAziz,Osama Abu Tabar et al.
Anas Hamad et al.
Background: Cancer remains a leading global health challenge, with high mortality rates and increasing financial burdens on healthcare systems. In the Gulf Cooperation Council countries, generic oncology medications offer a cost-effective a...
Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients [0.03%]
遗传性血管水肿患者的死亡率特征及共病情况
Subhan Khalid,Alan T Hitch
Subhan Khalid
Background: Patients with hereditary angioedema (HA) face a heightened mortality risk due to multiple factors. Objective: The purpose of this study was to identify patient demographics or comorbidities associated with higher mortality risk ...
Effect of Fresh Frozen Plasma Infusion on Hospital Length of Stay for Patients With Hereditary Angioedema [0.03%]
新鲜冷冻血浆输注对遗传性血管性水肿患者的住院时间的影响
Subhan Khalid,Alan T Hitch
Subhan Khalid
Background: Patients with hereditary angioedema treated with fresh frozen plasma (FFP) infusion face complications and risk of side effects. Objective: To study the effect of FFP infusion on hospital length of stay for patients with heredit...
Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients with Multifocal Motor Neuropathy: A US Claims Database Cohort Study [0.03%]
多灶性运动神经病患者的特征、治疗模式、医疗资源利用和成本：基于美国理赔数据库队列研究
Nikhil Khandelwal,Marie Sanchirico,Ade Ajibade et al.
Nikhil Khandelwal et al.
Background: Multifocal motor neuropathy (MMN) is a rare, slowly progressive nerve disorder characterized by asymmetric limb weakness without sensory abnormalities. MMN is often misdiagnosed due to similarities in clinical symptoms with cond...
Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data [0.03%]
高复发风险HR阳性、HER2阴性早期乳腺癌人群的规模及治疗结局：一项基于丹麦乳腺癌协作组注册登记资料的真实世界队列研究
Heidi Loponen,Juha Mehtälä,Laila Mehkri et al.
Heidi Loponen et al.
Background: While the prognosis is generally good for hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and/or pathologic featur...
The Impact of Enhanced Behavioral Health Services on Total Healthcare Costs Among US Employers: A Site-Level Analysis of 19 Cohort Studies [0.03%]
增强行为健康服务对美国雇主的总医疗费用的影响：19项队列研究的现场水平分析
Matt Hawrilenko,Casey Smolka,Emily Ward et al.
Matt Hawrilenko et al.
Background: The return on investment (ROI) of mental health care is a critical metric in an era of cost-conscious healthcare decision-making. However, selective reporting of positive study results may inflate ROI estimates. Objective: To qu...